Melanoma patient derived xenografts acquire distinct Vemurafenib resistance mechanisms

Variable clinical responses, tumor heterogeneity, and drug resistance reduce long-term survival outcomes for metastatic melanoma patients. To guide and accelerate drug development, we characterized tumor responses for five melanoma patient derived xenograft models treated with Vemurafenib. Three BRA...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Am J Cancer Res
Autori principali: Monsma, David J, Cherba, David M, Eugster, Emily E, Dylewski, Dawna L, Davidson, Paula T, Peterson, Chelsea A, Borgman, Andrew S, Winn, Mary E, Dykema, Karl J, Webb, Craig P, MacKeigan, Jeffrey P, Duesbery, Nicholas S, Nickoloff, Brian J, Monks, Noel R
Natura: Artigo
Lingua:Inglês
Pubblicazione: e-Century Publishing Corporation 2015
Soggetti:
Original Article
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC4473327/
https://ncbi.nlm.nih.gov/pubmed/26101714
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi